A new bladder cancer device called TAR-200 kept most patients cancer-free and surgery-free in a trial, with few side effects ...

NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions.

CIS with or without Papillary: Oral presentation from QUILT-3.032 study showed 71% complete response rate (N=100), with duration of response ranging up to more than 53 months, in BCG-unresponsive ...

AUA/SUO recommends that clinicians consider offering initial radical cystectomy for high-risk patients with persistent high-grade T1 disease on repeat resection, or T1 tumors with associated CIS ...

The U.S. Food and Drug Administration has approved Adstiladrin, which is being billed as the first gene therapy treating high-risk, non-muscle-invasive bladder cancer. Adstiladrin is a non-replicating ...

Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal.

Bladder cancer is typically diagnosed using a combination of urine cytology and white light cystoscopy, but some lesions—in particular dysplasia and carcinoma in situ (CIS)—can be missed with ...

CIS was found in 58 patients (29.6%), of whom 35 also had papillary tumors. A total of 113 CIS lesions were discovered, of which 104 (92%) were detected by HAL cystoscopy, 77 (68%) by white-light ...

However, reviewing the extended pelvic lymphadenectomy data in bladder cancer showed that several prospective and retrospective studies proved that the extent of lymphadenectomy and the number of ...

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and ...

The OS rate in trimodality treatment for bladder cancer ranged from 39 to 63% with a 5-year survival with preservation of the bladder of 36 to 43% ( Table 1 and Table 2 .